JPWO2020123508A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020123508A5 JPWO2020123508A5 JP2021532216A JP2021532216A JPWO2020123508A5 JP WO2020123508 A5 JPWO2020123508 A5 JP WO2020123508A5 JP 2021532216 A JP2021532216 A JP 2021532216A JP 2021532216 A JP2021532216 A JP 2021532216A JP WO2020123508 A5 JPWO2020123508 A5 JP WO2020123508A5
- Authority
- JP
- Japan
- Prior art keywords
- rnai construct
- pnpla3
- rnai
- nucleotides
- construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091030071 RNAI Proteins 0.000 claims 24
- 230000009368 gene silencing by RNA Effects 0.000 claims 24
- 125000003729 nucleotide group Chemical group 0.000 claims 13
- 230000000692 anti-sense effect Effects 0.000 claims 9
- 102100031251 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 Human genes 0.000 claims 8
- 101001129184 Homo sapiens 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 Proteins 0.000 claims 8
- 239000002773 nucleotide Substances 0.000 claims 8
- 108091081021 Sense strand Proteins 0.000 claims 6
- 238000000034 method Methods 0.000 claims 3
- 108700028369 Alleles Proteins 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 210000005229 liver cell Anatomy 0.000 claims 2
- 108091093094 Glycol nucleic acid Proteins 0.000 claims 1
- -1 bicyclic nucleic acid Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024065950A JP2024105284A (ja) | 2018-12-10 | 2024-04-16 | ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862777714P | 2018-12-10 | 2018-12-10 | |
| US62/777,714 | 2018-12-10 | ||
| PCT/US2019/065481 WO2020123508A2 (en) | 2018-12-10 | 2019-12-10 | Rnai constructs for inhibiting pnpla3 expression and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024065950A Division JP2024105284A (ja) | 2018-12-10 | 2024-04-16 | ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022511550A JP2022511550A (ja) | 2022-01-31 |
| JPWO2020123508A5 true JPWO2020123508A5 (enExample) | 2022-12-16 |
Family
ID=69024749
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532216A Pending JP2022511550A (ja) | 2018-12-10 | 2019-12-10 | ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト |
| JP2024065950A Pending JP2024105284A (ja) | 2018-12-10 | 2024-04-16 | ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024065950A Pending JP2024105284A (ja) | 2018-12-10 | 2024-04-16 | ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト及びその使用方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20220017906A1 (enExample) |
| EP (1) | EP3894555A2 (enExample) |
| JP (2) | JP2022511550A (enExample) |
| KR (1) | KR20210102932A (enExample) |
| CN (1) | CN113166761B (enExample) |
| AR (1) | AR117297A1 (enExample) |
| AU (1) | AU2019396419A1 (enExample) |
| BR (1) | BR112021011061A2 (enExample) |
| CA (1) | CA3121510A1 (enExample) |
| CL (1) | CL2021001489A1 (enExample) |
| CO (1) | CO2021008997A2 (enExample) |
| CR (1) | CR20210371A (enExample) |
| EA (1) | EA202191629A1 (enExample) |
| IL (1) | IL283473A (enExample) |
| JO (1) | JOP20210142A1 (enExample) |
| MX (1) | MX2021006784A (enExample) |
| NZ (1) | NZ776661A (enExample) |
| PE (1) | PE20211225A1 (enExample) |
| PH (1) | PH12021551326A1 (enExample) |
| SG (1) | SG11202105711SA (enExample) |
| TW (1) | TW202039843A (enExample) |
| UY (1) | UY38503A (enExample) |
| WO (1) | WO2020123508A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3283631A1 (en) | 2015-04-13 | 2018-02-21 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
| UY38003A (es) * | 2017-12-12 | 2019-06-28 | Amgen Inc | Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas |
| KR20220133248A (ko) | 2020-01-28 | 2022-10-04 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 pnpla3 좌위를 포함하는 비-인간 동물 및 사용 방법 |
| BR112023021109A2 (pt) * | 2021-04-14 | 2023-12-12 | Dicerna Pharmaceuticals Inc | Composições e métodos para modular a expressão de pnpla3 |
| EP4347823A1 (en) * | 2021-06-02 | 2024-04-10 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| EP4402262A1 (en) * | 2021-09-01 | 2024-07-24 | Aligos Therapeutics, Inc. | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof |
| CA3259147A1 (en) * | 2022-07-27 | 2024-02-01 | E-Therapeutics Plc | NUCLEIC ACID COMPOUNDS |
| WO2024120412A1 (en) * | 2022-12-07 | 2024-06-13 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of patatin-like phospholipase domain-containing 3 (pnpla3) |
| EP4463553B1 (en) * | 2022-12-19 | 2025-10-01 | Arnatar Therapeutics, Inc | Advanced rna targeting (arnatar) |
| CN121152879A (zh) * | 2023-02-14 | 2025-12-16 | 基愈治疗公司 | 经修饰的双链rna药剂 |
| WO2024182446A2 (en) * | 2023-02-28 | 2024-09-06 | Aligos Therapeutics, Inc. | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof |
| AU2024279767A1 (en) * | 2023-05-26 | 2025-12-04 | Adarx Pharmaceuticals, Inc. | Sod1-modulating compositions and methods of use thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| EP0916396B1 (en) | 1991-11-22 | 2005-04-13 | Affymetrix, Inc. (a Delaware Corporation) | Combinatorial strategies for polymer synthesis |
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5976567A (en) | 1995-06-07 | 1999-11-02 | Inex Pharmaceuticals Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| AU731909B2 (en) | 1997-07-01 | 2001-04-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| ATE237312T1 (de) | 1998-07-20 | 2003-05-15 | Protiva Biotherapeutics Inc | In liposomen verkapselte nukleinsäurekomplexe |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
| US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| JP4868739B2 (ja) | 2002-05-06 | 2012-02-01 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 核酸の送達法 |
| US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
| US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| US8017762B2 (en) | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
| CA2522637C (en) | 2003-04-17 | 2014-01-21 | Alnylam Pharmaceuticals, Inc. | Modified irna agents |
| US8877917B2 (en) | 2007-04-23 | 2014-11-04 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of RNA interference agents |
| CA2930393C (en) | 2007-12-04 | 2022-11-29 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| AR090905A1 (es) | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
| EP3564374A1 (en) | 2013-06-21 | 2019-11-06 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| JP2018510621A (ja) * | 2015-02-13 | 2018-04-19 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法 |
| EP3350328A1 (en) * | 2015-09-14 | 2018-07-25 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
| US10036024B2 (en) * | 2016-06-03 | 2018-07-31 | Purdue Research Foundation | siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD) |
| JP2020522510A (ja) * | 2017-06-02 | 2020-07-30 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド組成物及びその使用方法 |
| UY38003A (es) * | 2017-12-12 | 2019-06-28 | Amgen Inc | Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas |
-
2019
- 2019-12-10 KR KR1020217021155A patent/KR20210102932A/ko active Pending
- 2019-12-10 BR BR112021011061-5A patent/BR112021011061A2/pt unknown
- 2019-12-10 MX MX2021006784A patent/MX2021006784A/es unknown
- 2019-12-10 US US17/312,721 patent/US20220017906A1/en active Pending
- 2019-12-10 PH PH1/2021/551326A patent/PH12021551326A1/en unknown
- 2019-12-10 SG SG11202105711SA patent/SG11202105711SA/en unknown
- 2019-12-10 WO PCT/US2019/065481 patent/WO2020123508A2/en not_active Ceased
- 2019-12-10 CR CR20210371A patent/CR20210371A/es unknown
- 2019-12-10 PE PE2021000850A patent/PE20211225A1/es unknown
- 2019-12-10 EA EA202191629A patent/EA202191629A1/ru unknown
- 2019-12-10 UY UY0001038503A patent/UY38503A/es not_active Application Discontinuation
- 2019-12-10 NZ NZ776661A patent/NZ776661A/en unknown
- 2019-12-10 AU AU2019396419A patent/AU2019396419A1/en active Pending
- 2019-12-10 AR ARP190103607A patent/AR117297A1/es unknown
- 2019-12-10 CA CA3121510A patent/CA3121510A1/en active Pending
- 2019-12-10 CN CN201980081364.8A patent/CN113166761B/zh active Active
- 2019-12-10 JO JOP/2021/0142A patent/JOP20210142A1/ar unknown
- 2019-12-10 EP EP19828524.9A patent/EP3894555A2/en active Pending
- 2019-12-10 JP JP2021532216A patent/JP2022511550A/ja active Pending
- 2019-12-10 TW TW108145175A patent/TW202039843A/zh unknown
-
2021
- 2021-05-26 IL IL283473A patent/IL283473A/en unknown
- 2021-06-08 CL CL2021001489A patent/CL2021001489A1/es unknown
- 2021-07-08 CO CONC2021/0008997A patent/CO2021008997A2/es unknown
-
2024
- 2024-04-16 JP JP2024065950A patent/JP2024105284A/ja active Pending
-
2025
- 2025-01-17 US US19/029,290 patent/US20250320502A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024105284A5 (enExample) | ||
| TWI823866B (zh) | 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| JP2021506238A5 (enExample) | ||
| US9410154B2 (en) | HBV treatment | |
| JP2019122379A (ja) | 細胞内貫通能を持ってｒｎａ干渉を誘導する核酸分子およびその用途 | |
| JP2009513144A5 (enExample) | ||
| CA3189861A1 (en) | Dux4 inhibitors and methods of use thereof | |
| JPWO2020123508A5 (enExample) | ||
| AU2005290336A1 (en) | Method of treating an inflammatory disease by double stranded ribonucleic acid | |
| JP2011511636A5 (enExample) | ||
| JP2024109582A (ja) | トリループを含む二本鎖核酸インヒビター分子 | |
| CA3094008A1 (en) | Double-stranded nucleic acid inhibitor molecules modified with tm-increasing nucleotides | |
| JP2009531433A5 (enExample) | ||
| KR20230013266A (ko) | 올리고뉴클레오티드 | |
| WO2023227622A1 (en) | Oligonucleotides conjugated to oleic acid and uses thereof | |
| CN104031916B (zh) | 新型RNAi前体及其制备和应用 | |
| JPWO2020243702A5 (enExample) | ||
| JP2024513131A (ja) | オリゴヌクレオチド | |
| JPWO2023069754A5 (enExample) | ||
| US9790502B2 (en) | HBV treatment | |
| CA3254112A1 (en) | ARNI CONSTRUCTIONS THAT INHIBIT PNPLA3 EXPRESSION AND THEIR METHODS OF USE | |
| JP7208911B2 (ja) | 核酸分子発現の調節 | |
| WO2018014848A1 (zh) | 一种小rna抑制剂 | |
| WO2023168202A2 (en) | Certain dux4 inhibitors and methods of use thereof | |
| WO2024255749A1 (zh) | 靶向血管紧张素原的核酸及其用途 |